Triaza-spirodecanones as DDR1 inhibitors

A compound of formula (I)

• wherein
• L is —(CHR8)m—(CHR9)n—(CO)q—
• R1 is —NR6R7, aryl, or C3-7 cycloalkyl, wherein each of aryl, and C3-7 cycloalkyl and are optionally substituted with one or more R1′;
• each R1′ is independently selected from halogen, cyano, C1-7 alkyl, halo-C17 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C17 alkyl, phenyl, benzyl, amino, hydroxy, C1-7 alkoxy, halo-C1-7 alkoxy, C1-7 alkoxy-C1-7 alkyl, oxo, —CH2—OR16, —C(O)—OR16, —CH2—NHR16, —CH2—CH2—NR17R18, —CH2—C(O)—NHR16 and —C(O)—NHR16;
• or two R1′ together are —(CR12R13)s—;
• R2 is hydrogen, fluorine, C1-7 alkyl, or halo-C1-7 alkyl;
• R3 is hydrogen or C1-7 alkyl;
• R4 is aryl optionally substituted by one or more R4′;
• each R4′ is independently selected from halogen, cyano, C1-7 alkyl, halo-C1-7 alkyl, C3-7 cycloalkyl, amino, hydroxy, C1-7 alkoxy and halo-C1-7 alkoxy;
• R5 is indazole optionally substituted with one or more R5′;
• each R5′ is independently selected from halogen, cyano, C1-7 alkyl, halo-C1-7 alkyl, C3-7 cycloalkyl, amino, hydroxy, C1-7 alkoxy and —C(O)NH2;
• R6 is C1-7 alkyl, halo-C1-7 alkyl, hydroxy-C1-7 alkyl, C1-7 alkoxy-C1-7 alkyl, C3-7 cycloalkyl, aryl, —CH2—CH2—NR17R18, wherein C1-7 alkyl, C3-7 cycloalkyl, aryl or benzyl, are optionally substituted with one or more R6′;
• each R6′ is independently selected from halogen, cyano, C1-7 alkyl, halo-C1-7 alkyl, C3-7 cycloalkyl, amino, hydroxy, C1-7 alkoxy, halo-C1-7 alkoxy, C1-7 alkoxy-C1-7 alkyl, oxo, —CH2—C(O)—NHR16, phenyl, optionally substituted with C1-7 alkyl or benzyl;
• R7 is hydrogen, C1-7 alkyl, C3-7 cycloalkyl or is halo-C1-7 alkyl;
• R8 is hydrogen, C1-7 alkyl, hydroxy-C1-7 alkyl, C1-7 alkoxy-C1-7 alkyl, halo-C1-7 alkoxy-C1-7 alkyl, —(CH2)r-phenyl, or —(CH2)rNR10R11;
• R9 is hydrogen, C1-7 alkyl, or halo-C1-7 alkyl;
• R10 and R11 are independently selected from hydrogen and C1-7 alkyl;
• R12, R13, R14 and R15 are each independently selected from hydrogen, halogen and C1-7 alkyl;
• R16 is hydrogen, C1-7alkyl, halo-C1-7 alkyl or C3-7 cycloalkyl;
• R17 and R18 are independently selected from hydrogen and C1-7 alkyl;
• m is 0, 1 or 2;
• n is 0, 1 or 2;
• q is 0 or 1;
• r is 0, 1 or 2;
• s is 2, 3 or 4;
• or a pharmaceutically acceptable salt thereof;
• with the proviso that if R1 is —NR6R7 then:
• if q=0 then m+n≥2, or
• if q=1 then m+n≥1.